Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

Video

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Heinz Gisslinger, MD, professor, program director, Myeloproliferative Neoplasms, the Medical University of Vienna, discusses the 6-year event-free survival (EFS) data from the phase 3 PROUD-PV (NCT01949805) and CONTI-PV (NCT02218047) trials.

The PROUD-PV and CONTI-PV trials compared the efficacy and safety of ropeginterferon alfa-2b-njft (Besremi) vs hydroxyurea (Hydrea) or best available treatment in patients with polycythemia vera. A final efficacy analysis for CONTI-PV was conducted once all patients had completed 6 years of treatment. The maximum treatment duration was 7.3 years.

At the time of the final analysis, EFS, which was defined as time to death, disease progression, or thromboembolic events, was significantly higher in patients in the ropeginterferon arm than in those in the control arm, Gisslinger says. This higher probability of EFS in patients treated with ropeginterferon alfa-2b contributed to this regimen fulfilling the treatment goals of patients with polycythemia vera, Gisslinger concludes.

Related Videos
Mitchell S. Cairo, MD, and Sergio Giralt, MD, experts on veno-occlusive disease
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
A panel of 4 experts on hematologic malignancies
A panel of 4 experts on hematologic malignancies